MRC1 and neoplasm: In addition, 40 patients represented a CFDR with a single tumor and had an LAD within the range of 40–49 years and would thus initially be offered MMR functional analysis only (Fig. 2); as six of these patients had an MMR deficient tumor they would subsequently be offered mutation screening accordingly (Fig. 3a).